Tags

Type your tag names separated by a space and hit enter

Prostate-specific antigen may serve as a pathological predictor in breast cancer.
Rom J Morphol Embryol. 2008; 49(2):173-80.RJ

Abstract

PSA (prostate-specific antigen), a serine protease with chymotrypsin-like activity is the most useful tumor marker for prostate cancer screening, diagnosis, prognosis and monitoring. The identification of PSA in normal and tumoral mammary gland was regarded as a curiosity, but the confirmation of PSA expression in the mammary gland by others teams of researchers and the identification of specific mRNA in tumors with PSA immunoexpression initiated new perspectives for studies. The aim of this study was to examine the prevalence of PSA in breast cancers and to evaluate the correlations between PSA expression and some clinicopathological markers. We analyzed the expression of PSA in series of consecutive breast carcinomas by immunohistochemistry and correlated the PSA expression with the histological type and grade, nodal and metastasis status, estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and HER2/neu expression. PSA expression was observed in 44.5% of breast cancers, particularly in lobular types of carcinoma (p<0.0001). In univariate analysis, the expression of PSA was statistically correlated with AR (p<0.0001), PR (p=0.01) and inversely correlated with HER2/neu overexpression (p=0.008) and G3 (p=0.02). PSA did not significantly correlate with ER expression, lymph node and metastasis status. In multivariate analysis, PR was a moderate predictor (p=0.024) but the lobular type (p=0.000), AR (p=0.000), HER2/neu (p=0.002) and G3 (p=0.008) were strong predictors for PSA immunoexpression.

Authors+Show Affiliations

Department of Biochemistry, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. diana_narita@yahoo.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18516323

Citation

Nariţa, Diana, et al. "Prostate-specific Antigen May Serve as a Pathological Predictor in Breast Cancer." Romanian Journal of Morphology and Embryology = Revue Roumaine De Morphologie Et Embryologie, vol. 49, no. 2, 2008, pp. 173-80.
Nariţa D, Anghel A, Motoc M. Prostate-specific antigen may serve as a pathological predictor in breast cancer. Rom J Morphol Embryol. 2008;49(2):173-80.
Nariţa, D., Anghel, A., & Motoc, M. (2008). Prostate-specific antigen may serve as a pathological predictor in breast cancer. Romanian Journal of Morphology and Embryology = Revue Roumaine De Morphologie Et Embryologie, 49(2), 173-80.
Nariţa D, Anghel A, Motoc M. Prostate-specific Antigen May Serve as a Pathological Predictor in Breast Cancer. Rom J Morphol Embryol. 2008;49(2):173-80. PubMed PMID: 18516323.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prostate-specific antigen may serve as a pathological predictor in breast cancer. AU - Nariţa,Diana, AU - Anghel,A, AU - Motoc,Marilena, PY - 2008/6/3/pubmed PY - 2008/10/2/medline PY - 2008/6/3/entrez SP - 173 EP - 80 JF - Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie JO - Rom J Morphol Embryol VL - 49 IS - 2 N2 - PSA (prostate-specific antigen), a serine protease with chymotrypsin-like activity is the most useful tumor marker for prostate cancer screening, diagnosis, prognosis and monitoring. The identification of PSA in normal and tumoral mammary gland was regarded as a curiosity, but the confirmation of PSA expression in the mammary gland by others teams of researchers and the identification of specific mRNA in tumors with PSA immunoexpression initiated new perspectives for studies. The aim of this study was to examine the prevalence of PSA in breast cancers and to evaluate the correlations between PSA expression and some clinicopathological markers. We analyzed the expression of PSA in series of consecutive breast carcinomas by immunohistochemistry and correlated the PSA expression with the histological type and grade, nodal and metastasis status, estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and HER2/neu expression. PSA expression was observed in 44.5% of breast cancers, particularly in lobular types of carcinoma (p<0.0001). In univariate analysis, the expression of PSA was statistically correlated with AR (p<0.0001), PR (p=0.01) and inversely correlated with HER2/neu overexpression (p=0.008) and G3 (p=0.02). PSA did not significantly correlate with ER expression, lymph node and metastasis status. In multivariate analysis, PR was a moderate predictor (p=0.024) but the lobular type (p=0.000), AR (p=0.000), HER2/neu (p=0.002) and G3 (p=0.008) were strong predictors for PSA immunoexpression. SN - 1220-0522 UR - https://www.unboundmedicine.com/medline/citation/18516323/Prostate_specific_antigen_may_serve_as_a_pathological_predictor_in_breast_cancer_ L2 - http://www.rjme.ro/RJME/resources/files/490208173180.pdf DB - PRIME DP - Unbound Medicine ER -